Upstream Bio (UPB) Preferred Dividend Payments (2023 - 2024)
Upstream Bio's (UPB) quarterly Preferred Dividend Payments came in at $548000.0 in Q4 2024, down 82.61% year-on-year from $3.2 million in Q1 2024, and down 89.13% quarter-over-quarter from $5.0 million in Q3 2024.
Upstream Bio (UPB) Preferred Dividend Payments (2023 - 2024) Analysis & Trends
Upstream Bio's Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $548000.0 for Q4 2024.
- On a quarterly basis, Preferred Dividend Payments fell 82.61% year-over-year to $548000.0 in Q4 2024; TTM through Dec 2025 was $548000.0, a 95.97% decrease from a year earlier, with the FY2024 full-year figure at $13.6 million, down 23.3% from the prior year.
- Preferred Dividend Payments slipped to $548000.0 in Q4 2024 per UPB's latest filing, from $5.0 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $5.0 million in Q3 2024 and bottomed at $548000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Upstream Bio | 343.65 Mn | 343.65 Mn | -3.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 548,000.00 |
| Sep 30, 2024 | 5.04 Mn |
| Jun 30, 2024 | 4.88 Mn |
| Mar 31, 2024 | 3.12 Mn |
| Dec 31, 2023 | 3.15 Mn |
| Sep 30, 2023 | 3.15 Mn |